

Atty Docket No. 014137-00802 US/Cytel Ref. 100/80.2

PTO FAX NO.: 703/305-7939

ATTENTION: Examiner Thomas Cunningham
Group Art Unit 1816

DRAFT
FAX CENTER RECEIVED
JUN 24 1997

GROUP 1800

**PLEASE HAND DELIVER
TO EXAMINER THOMAS CUNNINGHAM**

OFFICIAL COMMUNICATION


**FOR THE PERSONAL ATTENTION OF
EXAMINER THOMAS CUNNINGHAM**

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following IS A COPY OF A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.98 WITH ATTACHED FORM PTO-1449 (THE ORIGINAL OF THIS SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT WITH REFERENCES WILL BE HAND DELIVERED TO YOU AS WE DISCUSSED), in re Application of Sette et al., Serial No. 08/452,843, filed 5/30/95, for HLA BINDING PEPTIDES AND THEIR USES is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page: 5

Dated: June 24, 1997


Mary Green

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
Telephone: 576-0200
Fax: 576-0300
pto-fax.mrg 5/96
F:\DATA\PS\PTOD\HAA\15734.1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231,
on

PATENT

TOWNSEND and TOWNSEND and CREW LLP

Attorney Docket No. 014137-008020US
FAX CENTER Cytel Ref. 100/80.2
RECEIVED

By _____

JUN 24 1997

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
Sette et al.) Examiner: T. Cunningham
Application No.: 08/452,843) Art Unit: 1816
Filed: 5/30/95) SUPPLEMENTAL INFORMATION
For: HLA BINDING PEPTIDES AND) DISCLOSURE STATEMENT UNDER
THEIR USES) 37 CFR §1.97 and §1.98
)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. A copy of each is enclosed.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to charge such fee to Deposit Account

Sette et al.


Application No.: 08/452,843

Page 2

PATENT

No. 20-1430. Please charge any additional fees or credit any overpayment to the above-noted Deposit Account.

Respectfully submitted,



Dated: 6/24/97

Hector A. Alicea, Ph.D.
Reg. No. P-40,891

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 576-0200
Fax (415) 576-0300
HAA:meg

f:\data\ps\ptod\haa\75729.1

| FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Attorney Docket No. 014137- 008020US/Cytel Ref. 100/80.2 | Serial No.: 08/452,843 |
|---|---|---|---------------------------|
| Applicant: Sette et al. | | | |
| | | Filing Date: 5/30/95 | Group: 1816 |
| Reference Designation | | U.S. PATENT DOCUMENTS | |
| Examiner Initial | Document No. | Date | Name |
| | | | |
| <u>AA</u> | | | |
| <u>AB</u> | | | |
| <u>AC</u> | | | |
| <u>AD</u> | | | |
| <u>AE</u> | | | |
| <u>AF</u> | | | |
| <u>AG</u> | | | |
| <u>AH</u> | | | |
| <u>AI</u> | | | |
| <u>AJ</u> | | | |
| <u>AK</u> | | | |
| <u>AL</u> | | | |
| FOREIGN PATENT DOCUMENTS | | | |
| | Document No. | Date | Country |
| <u>AM</u> | WO 94/11738 | 26 May 1994 | PCT |
| <u>AN</u> | | | |
| <u>AO</u> | | | |
| <u>AP</u> | | | |
| <u>AQ</u> | | | |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| <u>AR</u> | Hill, Adrian V.S. et al., <i>Nature</i> 360:434-439 (1992) | | |
| <u>AS</u> | Falk, Kirsten et al., <i>Immunogenetics</i> 38:161-162 (1993) | | |
| <u>AT</u> | Falk, Kirsten et al., <i>Proc. Natl. Acad. Sci. USA</i> 90:12005-12009 (1993) | | |

**LIST OF PATENTS AND
PUBLICATIONS FOR APPLICANT'S
INFORMATION DISCLOSURE
STATEMENT**
(Use several sheets if necessary)

Attorney Docket No.
014137-
008020US/Cytel Ref.
100/80.2

Serial No.:
08/452,843

Applicant: Sette et al.

Filing Date:
5/30/95

Group: 1816

| | |
|----|---|
| AU | Falk, Kirsten et al., <i>Immunogenetics</i> 39:230-242 (1994) |
| AV | Falk, Kirsten et al., <i>Immunogenetics</i> 40:238-241 (1994) |
| AW | Rötzschke, Olaf et al., <i>Current Opinion in Immunology</i> 45-51 (1994) |
| AX | Fujii et al., <i>Chem. Pharm. Bull.</i> 31(12):4259-4262 (1983), "Studies on peptides. CXIV. Synthesis of hylambates-kassinin, a frog skin tachykinin peptide". |
| AY | Park et al., <i>Can. J. Biochem.</i> 56(2):92-100 (1978), "Synthesis of peptides by the solid-phase method. III bradykinin: fragments and analogs". |
| AZ | Rudinger, J. in <i>Peptide Hormones</i> , edited by J.A. Parsons, University Park Press, Baltimore, MD, pages 1-7 (1976) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.